ALAMEDA, Calif., Nov. 30, 2018 (GLOBE NEWSWIRE) — OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of lung cancer, today announced that the Company will provide a corporate overview at the LD Micro 11th Annual Main Event Investor Conference, being held December 4-6, 2018 at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.
OncoCyte Corporation Presentation Details:
Date: Tuesday, December 4
Time: 8:00am Pacific Time/11:00am Eastern Time
Location: Luxe Sunset Boulevard Hotel
About OncoCyte Corporation
OncoCyte is focused on the development and commercialization of novel, non-invasive blood (“liquid biopsy”) diagnostic tests for the early detection of lung cancer. Early detection of cancer can improve health outcomes, reduce the cost of care, and improve patients’ quality of life. Liquid biopsy diagnostic tests like those OncoCyte is developing may reduce the need for costlier and riskier diagnostic procedures such as invasive biopsy and cystoscopic procedures. OncoCyte is focusing its efforts on the development of DetermaVu™ as a non-invasive confirmatory diagnostic test for lung cancer. DetermaVu™ is being developed using proprietary sets of genetic molecular markers that differentially express in lung cancer. OncoCyte also plans to conduct research to identify additional molecular markers, acquire or license markers and related technology, and develop cancer tests based on those markers.
Contact:
Bob Yedid
LifeSci Advisors, LLC
646-597-6989
bob@lifesciadvisors.com